Abstract 731P
Background
In Part 1 of the phase 3 ENGOT-EN6-NSGO/GOG-3031/RUBY trial (NCT03981796), dostarlimab+carboplatin-paclitaxel (DOST+CP) significantly improved PFS (HR 0.64) and OS (HR 0.69) vs placebo (PBO)+CP in the overall population of pts with pA/rEC. Limited data are available on outcomes with follow-up anticancer treatment (FUACT) after DOST+CP. Here we report post-progression survival outcomes of pts in the overall and mismatch repair proficient/microsatellite stable (MMRp/MSS) populations who received FUACT of immunotherapy (IO).
Methods
Pts were randomized 1:1 to receive DOST/PBO+CP Q3W (6 cycles) followed by DOST/PBO monotherapy Q6W for ≤3 years. At interim analysis 2 (37.2 mo of follow-up), updated post hoc analyses of OS adjusted for treatment switching via rank-preserving structural failure time (RPSFT) were performed in the overall and MMRp/MSS populations of pts who received FUACT of IO and for pts receiving pembrolizumab-lenvatinib (PEM-LEN) in the MMRp/MSS population.
Results
In total, 494 pts were randomized (table). FUACT of IO was received by 137 and 102 pts in the overall and MMRp/MSS populations, respectively; PEM-LEN was received by 65 pts in the MMRp/MSS population. Approximately twice as many patients received FUACT of IO in the PBO+CP vs DOST+CP arm. When adjusted for subsequent IO, RPSFT analyses showed HRs of 0.63 (overall) and 0.76 (MMRp/MSS) for DOST+CP vs PBO+CP, consistent with the unadjusted HRs for OS in the primary analysis. In the MMRp/MSS population receiving subsequent PEM-LEN, HR of RPSFT-adjusted OS was also consistent at 0.77.
Table: 731P
Overall | MMRp/MSS | |||
DOST+CP | PBO+CP | DOST+CP | PBO+CP | |
N | 245 | 249 | 192 | 184 |
OS (95% CI) | 0.69(0.54–0.89) | 0.79(0.60–1.04) | ||
Any FUACT, n, % | ||||
Any IO a | 42 (17.1) | 95 (38.2) | 34 (17.7) | 68 (37.0) |
PEM-LEN | 25 (10.2) | 45 (18.1) | 22 (11.5) | 43 (23.4) |
RPSFT-adjusted OS | ||||
Follow-up any IO HR (95% CI) | 0.63(0.46–0.87) | 0.76(0.54–1.06) | ||
AF b | 1.64 | 1.28 | ||
Follow-up PEM-LENHR (95% CI) | — | 0.77 (0.56–1.06) | ||
AF b | — | 1.25 |
aImmunotherapies: PEM, PEM-LEN, PEM-tamoxifen, DOST, retifanlimab/epacadostat, durvalumab combinations, investigational product, atezolizumab combinations, bevacizumab/atezolizumab, MK7694A, and nivolumab combinations.
bDOST+CP increases survival by acceleration factor (AF).
Conclusions
Adjusted OS using RPSFT for subsequent use of IO in the overall and MMRp/MSS populations, including PEM-LEN in the MMRp/MSS population, showed limited impact on survival benefits, supporting frontline use of dostarlimab+CP as standard of care in all pts with pA/rEC.
Clinical trial identification
NCT03981796.
Editorial acknowledgement
Writing and editorial support, funded and coordinated by GSK, was provided by Shannon Morgan-Pelosi, PhD, CMPP, and editor TBD, of Ashfield MedComms, an Inizio company.
Legal entity responsible for the study
GSK.
Funding
GSK.
Disclosure
M.R. Mirza: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Biocad, GSK, Karyopharm, Merck, Roche, Zailab; Financial Interests, Institutional, Research Funding: Apexigen, AstraZeneca, Deciphera (trial chair), GSK, Ultimovacs; Financial Interests, Personal, Stocks/Shares: Karyopharm ; Financial Interests, Personal, Member of Board of Directors: Karyopharm. C. Mathews: Financial Interests, Institutional, Research Grant: Astellas, AstraZeneca, Deciphera, Moderna, GSK, Regeneron, Seattle Genetics; Financial Interests, Personal, Advisory Board: IMAB biopharma. L. Gilbert: Financial Interests, Institutional, Advisory Board: Alkermes, AstraZeneca, Clovis, Corcept Therapeutics, Esperas, GOG Foundation, GSK, ImmunoGen, IMV, K-Group Beta, Karyopharm, Merck Sharp & Dohme, Mersana Therapeutics, Novocure GmbH, OncoQuest Pharmaceuticals, Roche, Shuttuck Labs, Sutro BioPharma Inc, Tesaro; Financial Interests, Personal, Speaker, Consultant, Advisor: GSK, Merck; Financial Interests, Personal, Other, honoraria: CanariaBio, Eisai, Eisai-Merck, GOG Foundation, GSK, ImmunoGen, Kora Healthcare, Merck; Financial Interests, Personal, Other, travel support: EndomEra, GOG Foundation, GSK, Merck, Zentalis; Financial Interests, Personal, Other, participation on a Data Safety Monitoring Board: CanariaBio, Eisai, Eisai-Merck, GOG Foundation, GSK, ImmunoGen, Kora Healthcare, Merck. L. Bjorge: Financial Interests, Personal, Speaker, Consultant, Advisor: GSK. M.A. Powell: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Clovis Oncology, Eisai, GSK, Merck, Seagen, Tesaro. T. Van Gorp: Financial Interests, Institutional, Research Funding: Amgen, AstraZeneca, Roche; Financial Interests, Institutional, Speaker, Consultant, Advisor: AbbVie, AstraZeneca, BioNTech, Cancer Communications and Consultancy Ltd, Eisai, GSK, ImmunoGen, Inc., Incyte, Karyopharm, MSD/Merck & Co., OncXerna Therapeutics, Seagen, Tubulis, Zentalis; Financial Interests, Institutional, Other, Support for attending meetings and/or travel: AstraZeneca, ImmunoGen, Inc., MSD/Merck, PharmaMar; Financial Interests, Personal, Non remunerated activity, Chair: Belgian and Luxembourg Gynaecological Oncology Group. D. Bender: Financial Interests, Institutional, Other, grants: AbbVie, AstraZeneca, Clovis Oncology Inc, Genentech, MSD, Tesaro. G. Canturia: Financial Interests, Personal, Speaker, Consultant, Advisor: GSK; Other, Personal, Other, patent on an anti-tumor lipid molecule that is early stage of development: TBD. R. Gogoi: Non-Financial Interests, Personal, Advisory Board, or data safety monitoring board: Pionyr Pharmaceuticals; Financial Interests, Personal, Other, receipt of equipment, materials, drugs, medical writing, gifts or other services: Bausch + Lomb. G. Antony: Financial Interests, Personal, Full or part-time Employment: GSK. S. Stevens: Financial Interests, Personal, Full or part-time Employment: GSK. G. Valabrega: Financial Interests, Personal, Speaker, Consultant, Advisor: GSK; Financial Interests, Personal, Other, honoraria: AstraZeneca, GSK, MSD; Financial Interests, Personal, Other, travel support: AstraZeneca, PharmaMar; Non-Financial Interests, Personal, Advisory Board: AstraZeneca, EISAI, GSK, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
722P - Long-term patient-reported outcomes (PROs) with atezolizumab (atezo) + bevacizumab (bev) and chemotherapy (CT) for metastatic, persistent or recurrent cervical cancer (R/M CC): BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial
Presenter: Laurence Gladieff
Session: Poster session 01
723P - A phase II study of cadonilimab plus chemotherapy in persistent recurrent/ metastatic cervical cancer patients who failed previous immuno/chemotherapy
Presenter: Li Xiaoling Li
Session: Poster session 01
724P - Preliminary outcomes from a phase Ib/II study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer
Presenter: Guiling Li
Session: Poster session 01
725P - Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group
Presenter: Dominik Denschlag
Session: Poster session 01
726P - Efficacy and safety of pembrolizumab plus olaparib combination therapy in recurrent cervical cancer progressed on platinum-based chemotherapy: Results from the phase II trial of GOTIC-025
Presenter: Kosei Hasegawa
Session: Poster session 01
727P - Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China
Presenter: Yang Sun
Session: Poster session 01
Resources:
Abstract
728P - Chemotherapy plus tislelizumab in young patients with cervical cancer preserve fertility: A phase II study
Presenter: Danbo Wang
Session: Poster session 01
729P - Patterns of survivorship care of cervical cancer patients with or without HIV infection in Botswana 2015-2022
Presenter: Sheldon Amoo-Mitchual
Session: Poster session 01
730P - Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA
Presenter: Guillaume Beinse
Session: Poster session 01
732P - Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
Presenter: Stephanie Blank
Session: Poster session 01